Excalipoint closes $68.7M seed round for cancer T-cell engagers

AI Briefing

• – Excalipoint Therapeutics secures $68.7M seed funding to advance T-cell engagers for solid tumors.
• – This marks one of the largest early stage financings in China biotech history.
• – The company will use the funds to further develop its portfolio of T-cell engagers.